Rudy Dekeyzer

Dr. Rudy Dekeyser is Partner at LSP, a leading European venture capital firm with 2 billion Euro under management and investing in healthcare companies from seed to late stage in the fields of drug discovery, drug development, medical devices, diagnostics and digital health. Prior to joining LSP in 2012, Rudy has been managing director of VIB, an entrepreneurial life sciences research institute which he co-founded with Jo Bury in 1995. Rudy has also been intimately involved in the foundation of several bio-incubators, bio-accelerators, the European Association of Science and Technology Managers and Oncode, a Dutch research institute in the field of cancer. Rudy has been/is chairman/non-executive director at Ablynx (acquired by Sanofi), Actogenix (acquired by Intrexon), Multiplicom (acquired by Agilent), CropDesign (acquired by BASF), Devgen (acquired by Syngenta), QBiologicals (acquired by Amatsi), Curetis (listed), Sequana Medical (listed), Celyad (listed) and Lumeon and is also chairman/board member of several non-profit life sciences initiatives such as EMBLEM, De Weijerhorst Stichting, Fonds Généret and the Fonds Fournier-Majoie.

October 01, 2019 Hubrecht Organoid Technology and MIMETAS to d... Leiden, Utrecht September 2019 MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategi... read more
July 17, 2019 Epistem license Hubrecht Organoid Technology ... Epistem license Hubrecht Organoid Technology to expand preclinical toxicology service portfolio Manchester, 16th July, 2... read more
July 09, 2019 ‘Het gaat alleen sneller als er geld bij ko... Hubrecht Organoid Technology, kortweg HUB, is als start-up ontstaan op de Uithof, de universiteitscampus in Utrecht. Het... read more